Radiopharm Theranostics RADX
NASDAQ RADX
$0.88 -0.07 (-7.70%)
At close: Nov 9, 2026 · 4:00 PM EST

Radiopharm Theranostics (RADX) Ending Cash Balance (2023 - 2025)

Updated

Analysis

Radiopharm Theranostics (RADX) Ending Cash Balance (2023 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Ending Cash Balance (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn 4.89 Bn
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn 16.91 Bn
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn 10.77 Bn
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn 9.65 Bn
5 Novartis Ag 316.85 Bn 290.09 Bn - -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn 7.94 Bn
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn 13.19 Bn
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn 6.44 Bn
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn 1.88 Bn
10 Radiopharm Theranostics 2.70 Bn 2.62 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 18.58 Mn
Jun 30, 2024 11.70 Mn
Jun 30, 2023 26.98 Mn
API Access

Radiopharm Theranostics Ending Cash Balance API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ending-cash-balance&ticker=RADX&period=max&api_key=YOUR_API_KEY